Industry Background:
Hydroxyethyl starch is used to prevent blood loss in the case of surgeries, trauma, and others for critically ill patients. It is used as a volume expander for the circulatory system in intravenous therapy. The increasing number of critically ill patients and the growing geriatric population are major growth factors of the market. Moreover, growing healthcare infrastructure in the developing economies expected to fuel the market growth during the forecasted period.This growth is primarily driven by Reduces Blood Loss During Caused By Surgery and Growing Demand from the Medical Industry.
Globally, a noticeable market trend is evident Increasing Application in Intravenous Therapy. Major Vendors, such as Skyrun Industrial (China), Hangzhou J&H Chemical (China), Hefei Hirisun Pharmatech (China), AK Scientific (United States), Carbone Scientific (United Kingdom), Kinbester (China), Leap Labchem (China) and Chengdu Bojia Pharmaceutical (China) etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.
Key Developments in the Market:
In Jan 2018, The CMDh1 has decided that hydroxyethyl starch (HES) solutions for infusion should remain on the market provided that a combination of additional measures to protect patients is implemented. This follows further reflection, in consultation with EU Member States, on whether it would be feasible to introduce new measures that would effectively reduce the risks with these medicines.
In Jan 2018, EMA's Pharmacovigilance Risk Assessment Committee (PRAC) has recommended the suspension of the marketing authorizations for hydroxyethyl-starch (HES) solutions for infusion across the European Union. These products are used as plasma volume replacement following acute (sudden) blood loss, where treatment with alternative products known as 'crystalloids' alone is not considered to be sufficient.
Regulatory Insights:
“A key event in the regulation of HES occurred in 2013 when both the Food and Drug Administration and the European Medicines Agency advised against its use in critically ill patients, including patients with sepsis. Several largerandomized controlled trials (RCTs) on volume resuscitation in critical illness with low risk of bias failed to observe clinically beneficial effects of HES and confirmed previous doubts regarding the safety profile of tetra starches.”
Market Drivers
- Reduces Blood Loss During Caused By Surgery
- Growing Demand from the Medical Industry
Market Trend
- Increasing Application in Intravenous Therapy
Restraints
- Stringent Government Regulations for the Medical Use of Hydroxyethyl Starch
Opportunities
Increasing Number of Surgical Procedures and Growing Healthcare Infratstrure in Developing Economies
Challenges
Adverse Effects Such As Mild Influenza-Like Symptoms, Hypersensitivity, Fast Heart Rate, Slow Heart Rate, And Others
AMA Research follow a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcase the spontaneously changing Vendors landscape impacting the growth of the market. Furthermore, our market researchers extensively analyse the products and services offered by multiple players competing to increase their market share and presence.
Customization in the Report
AMA Research features not only specific market forecasts, but also include significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints
- New Entrants into the Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis
Against this Challenging Backdrop, Hydroxyethyl Starch Study Sheds Light on
— The Hydroxyethyl Starch Market status quo and key characteristics. To end this, Analyst at AMA organize and took survey of the Hydroxyethyl Starch industry Vendors. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Hydroxyethyl Starch industry is heading and what are the top priorities. Insights are drawn from financial analysis, the survey and interviews with key executives and industry experts.
— How every company in this diverse set of Vendors can best navigate the emerging competition landscape and follow a strategy that helps them position to hold value they currently claim, or capture the new addressable opportunity.